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Perspectives
P
araquat is a contact herbicide 
(one that kills plants by contact 
rather than being taken up in 
the roots and acting systemically) that 
is extensively used in agriculture, as 
it is fast-acting and non-persistent in 
the environment. It has, however, 
one major problem—its toxicity 
when ingested. The mechanisms of 
this toxicity are well understood and 
were described in detail over 20 years 
ago [1]. Paraquat is marketed for 
agricultural use as a concentrated 
solution, and in this form it is estimated 
that as little as a mouthful ingested is 
likely to be fatal. 
Blood levels of paraquat are 
indicative of outcome [2], but many 
patients have levels over 100 times the 
estimated lethal concentration, making 
treatment extremely difﬁcult. In these 
patients, death may occur within a 
few hours from multi-organ toxicity. 
In less severe cases renal failure and 
gastrointestinal upset occur, resulting 
in death within two or three days if 
untreated. If these complications 
are managed by haemodialysis 
and ﬂuid resuscitation, pulmonary 
ﬁbrosis follows due to redox recycling 
(repetitive oxidation and reduction of 
the molecule, using up cellular energy) 
of paraquat in the lung. Death is then 
secondary to anoxia several days later; 
early oxygen treatment is thought to 
increase the risk of lung damage as it 
fuels the redox process. 
Twenty years ago it was clear that 
treatments for paraquat poisoning were 
ineffective and that new approaches 
to managing such poisoning were 
required [3]. In the intervening period, 
small-scale studies have suggested a 
potential role for immunosuppressants 
[4] in preventing death from lung 
injury, but the efﬁcacy of this treatment 
remains in doubt [5].
Is the New Paraquat Formulation 
Safer?
The agribusiness company Syngenta 
has attempted to go back to a ﬁrst 
principle of poisoning prevention: 
that is, to change the formulation of 
the marketed product in an attempt to 
reduce human systemic exposure, and 
hence toxicity. Although paraquat has 
long contained an emetic, Syngenta has 
increased its concentration, added a 
purgative (magnesium sulphate), and 
included an alginate designed to cause 
gel formation of ingested product 
and thus delay absorption, with the 
intention of giving the emetic more 
opportunity to work. 
In this issue of PLoS Medicine, Martin
Wilks (of Syngenta Crop Protection 
AG) and colleagues report the results 
of an impressive clinical study in Sri 
Lanka of the new formulation [6]. 
Data on exposure, treatment, and 
outcome of patients who ingested 
paraquat were prospectively collected 
at nine hospitals from December 2003 
to January 2006. The new paraquat 
formulation was introduced in October 
2004. The identity of the formulation 
ingested after October 2004 was 
determined by blood or urine samples. 
The researchers compared mortality in 
those admitted during a control period 
before October 2004 (i.e., those who 
ingested the old paraquat formulation) 
with mortality in those who ingested 
the new product. The primary outcome 
measure was survival to three months.
Of the 297 patients who ingested the 
standard formulation, there were 221 
deaths, while of the 289 patients who 
ingested the new formulation, there 
were 186 deaths. The mortality rate 
at three months was 72.9% for those 
who ingested the standard formulation 
compared with 63.3% for those who 
ingested the new formulation. Median 
time to death changed from only 
0.9 days to 1.5 days after introducing 
the new formulation. Such a rapid 
progression to death indicates the 
magnitude of the doses ingested in 
this patient group, both before and 
after formulation change. The net 
overall effect of the change was to 
produce one more survivor for every 
ten patients poisoned. This would 
appear impressive, if it were not for 
the fact that between six and seven of 
every ten patients who ingest the new 
formulation still die.
A Step in the Wrong Direction?
Although the reasons for the 
multiple formulation changes were 
clear to the authors prior to study 
commencement, these reasons are 
not well presented in their paper, 
making this reader feel their logic was 
New Formulation of Paraquat: 
A Step Forward but in the Wrong Direction?
D. Nicholas Bateman
Funding: The author received no speciﬁc funding for 
this article. 
Competing Interests: One of the authors of the 
study discussed in this perspective (M. Eddleston) 
works in DNB’s department.
Citation: Bateman DN (2008) New formulation 
of paraquat: A step forward but in the wrong 
direction? PLoS Med 5(2): e58. doi:10.1371/journal.
pmed.0050058
Copyright: © 2008 D. Nicholas Bateman. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited.
D. Nicholas Bateman is Professor of Clinical 
Toxicology, Royal Inﬁrmary of Edinburgh, Edinburgh, 
United Kingdom. E-mail: nick.bateman@luht.scot.
nhs.uk
The Perspectives section is for experts to discuss the 
clinical practice or public health implications of a 
published article that is freely available online.
Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Wilks MF, Fernando R, Ariyananda 
PL, Eddleston M, Berry DJ, et al. (2008) 
Improvement in survival after paraquat 
ingestion following introduction of a new 
formulation in Sri Lanka. PLoS Med 5(2): 
e49. doi:10.1371/journal.pmed.0050049
Martin Wilks and colleagues compared 
the outcome of paraquat self-poisoning 
with the standard formulation against 
a new formulation following its 
introduction into Sri Lanka.PLoS Medicine  |  www.plosmedicine.org 0186 February 2008  |  Volume 5  |  Issue 2  |  e58
perhaps confused. A recent study of 
paraquat plasma kinetics in rabbits 
shows that inclusion of alginate causes 
a reduction in paraquat absorption in 
vivo in this species—the area under 
the curve (0–24 h) was reduced from 
33.8 +/- 3 microg.mL-1h for paraquat 
(Gramoxone) to 12.5 +/- 6 
microg.mL-1h with an alginate 
formulation [7]. To be effective 
clinically, this magnitude of effect 
would be most likely to work in patients 
near to a fatal threshold dose. In the 
present study, the median mortality 
time in the baseline period was less 
than one day, indicating a very large 
median ingested dose of concentrated 
paraquat. Most European toxicologists 
will have seen relatively few patients 
who die in this very short time frame, as 
most patients take lesser doses and die 
from the later pulmonary ﬁbrosis.
There was some internal 
inconsistency in the approaches used 
to alter the formulation, in that gastric 
emptying was intended to be delayed 
by the use of an alginate that would gel 
in gastric acid. However, since emetics 
work predominantly after passive 
absorption from the small bowel, their 
absorption is necessarily coincident 
with the active uptake of the paraquat 
in the small bowel. Emetics may also 
alter small bowel motility by inducing 
reverse peristalsis—hence the overall 
approach seems a little confused. 
Uptake of paraquat from the small 
bowel is rapid, and it was perhaps 
optimistic to think that magnesium 
sulphate would prevent absorption 
of sufﬁcient quantity of paraquat by 
speeding its passage through the small 
bowel in this Sri Lankan patient group.
Quantities of paraquat ingested 
in this study were very substantial, 
and the overall approach of this new 
formulation would only be effective if 
a very high proportion of patients are 
very close to the borderline between 
a lethal and non-lethal dose—much 
lower than the median doses ingested 
by patients in this study. Although 
the change in paraquat formulation 
might have had an impact in Europe, 
where lower doses are usually ingested, 
such a change is now not needed 
as legislation has limited general 
access. As happened in the United 
Kingdom, Europe will remove the 
product completely [8]. In the more 
afﬂuent countries of the world, toxicity 
prevention by product ban may be 
achievable, but seems less readily 
acceptable in the economic margins of 
subsistence farming. 
Where to Go From Here: A 
Signpost for the Future?
Wilks and colleagues’ study clearly 
shows the difﬁculty of a harm-reduction 
campaign based on formulation change 
for paraquat in this environment. 
Prevention strategies are not however 
an impossible objective. If paraquat use 
is to continue, and we are told it will 
in Asia for the foreseeable future, then 
the answer must be to make it more 
difﬁcult for the product to be swallowed 
in the heat of an emotional crisis. 
Storage away from the home is 
one target for prevention, but use of 
communal locked storage facilities and 
independent keys for access may not be 
accepted and hence may be ineffective 
[9]. A second target would be attempts 
to further address formulation and 
packaging. Using the alginate to gel the 
concentrate might be one approach, 
making rapid swallowing difﬁcult. 
Mixing would be required prior to 
application.
A ﬁnal, more easily deliverable 
target, given the evident toxicity of the 
high concentrates used in Sri Lanka, is 
to consider using more dilute paraquat 
preparations as the primary product for 
agricultural use. It appears that such an 
approach is now being implemented 
in Sri Lanka [10]. This approach has 
implications for transport, both to and 
within the farm, but such a price seems 
worth paying—if it would reduce the 
number of early untreatable patients 
reported here and perhaps prevent 
so many young and needless deaths. 
All new approaches need testing, and 
Wilks and colleagues have the expertise 
needed for such evaluation. 
The Take-Home Message
Paraquat remains a poison for which 
there is still little strong evidence 
of effective therapies. It has caused 
signiﬁcant mortality worldwide for 
over 30 years. If it is to remain in 
use, then studies such as the one by 
Wilks and colleagues are important. 
In retrospect, it can easily be seen 
that the new paraquat formulation 
was unlikely to be a major advance 
in this environment. We should 
therefore use the ﬁndings of the 
new study to focus attention on 
simple strategies to reduce paraquat-
induced death (and morbidity from 
this and other pesticides) in Asia. 
Immunosuppressants after overdose 
are not the solution.  
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